pembrolizumab,olaparib,enzalutamide,abiraterone,bevacizumab
janssen,astrazeneca,astellas,merck,pfizer,roche
['keytruda', 'lynparza', 'xtandi', 'crpc', 'zytiga', 'pfizer', 'astellas']
compared with either j&amp;j's zytiga or astellas and pfizer's xtandi, the lynparza-keytruda combo offered no benefits in mcrpc. 
Tweets from the Fierce Life Sciences editorial team